Point72 Asia (Singapore) Pte. Ltd. Protalix Bio Therapeutics, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $532 Billion
- Q3 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 47,073 shares of PLX stock, worth $116,741. This represents 0.01% of its overall portfolio holdings.
Number of Shares
47,073
Previous 68,163
30.94%
Holding current value
$116,741
Previous $79.8 Million
39.8%
% of portfolio
0.01%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding PLX
# of Institutions
51Shares Held
3.58MCall Options Held
61.1KPut Options Held
36.2K-
Jim Simons Renaissance Technologies LLC | New York, Ny956KShares$2.37 Million0.0% of portfolio
-
Gsa Capital Partners LLP London, X0435KShares$1.08 Million0.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny374KShares$926,9170.0% of portfolio
-
Black Rock Inc. New York, NY333KShares$826,2640.0% of portfolio
-
Stratos Wealth Partners, Ltd.270KShares$669,6000.01% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $123M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...